ARRAY BIOPHARMA INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
ARRAY BIOPHARMA INC. - More news...
ARRAY BIOPHARMA INC. - More news...
- Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
- BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
- The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
- Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib)
- Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer
- Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer
- Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma
- Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference
- Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting
- Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference
- Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018
- Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018
- Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
- Array BioPharma To Present At The Cowen 38th Annual Healthcare Conference
- Array BioPharma To Present At The LEERINK Partners 7th Annual Global Healthcare Conference
- Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
- Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
- Array BioPharma Inc. to Host Earnings Call
- Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018
- Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial
- Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers Symposium
- Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference
- Lifshitz & Miller LLP Announces Investigation of Alteryx, Inc., Array BioPharma Inc., Bruker Corporation, Eagle Bancorp, Inc., Omega Healthcare Investors, Inc., Otsuka Holdings Co., Ltd., Tivity Health, Inc. and Triangle Capital Corporation
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY
- Array BioPharma Announces Redemption of All Remaining 3.00% Convertible Senior Notes Due 2020
- ARRAY BIOPHARMA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The Firm
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline: January 22, 2018
- Array BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference
- Array BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Array Biopharma, Inc. - ARRY
